第一医药(600833) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥503,963,782.80, representing a 9.07% increase compared to ¥462,073,365.11 in the same period last year[3]. - Net profit attributable to shareholders decreased by 86.86% to ¥4,739,088.09 from ¥36,053,836.02 year-on-year[3]. - Basic earnings per share fell by 86.88% to ¥0.0212 from ¥0.1616 in the previous year[3]. - Operating profit for Q1 2025 decreased to RMB 6,843,250.78 from RMB 8,042,027.64 in Q1 2024, a decline of 14.9%[16]. - Net profit for Q1 2025 was RMB 4,803,479.29, down 89.9% from RMB 47,904,890.21 in Q1 2024[16]. - The total comprehensive income attributable to the parent company's owners for Q1 2025 was ¥4,274,472.88, compared to ¥37,015,409.34 in Q1 2024[17]. Cash Flow - The net cash flow from operating activities increased by 22.45% to ¥12,696,455.52 compared to ¥10,368,722.94 in the same period last year[3]. - Cash inflows from operating activities for Q1 2025 amounted to ¥586,079,255.12, an increase from ¥524,458,564.26 in Q1 2024[21]. - The net cash flow from operating activities for Q1 2025 was ¥12,696,455.52, compared to ¥10,368,722.94 in Q1 2024[21]. - Cash inflows from investment activities for Q1 2025 were ¥227,247,569.32, significantly higher than ¥90,261,106.91 in Q1 2024[21]. - The net cash flow from investment activities for Q1 2025 was ¥13,110,527.31, recovering from a net outflow of -¥23,321,084.87 in Q1 2024[22]. - The net cash flow from financing activities for Q1 2025 was -¥52,003,720.06, compared to a positive net flow of ¥4,362,688.95 in Q1 2024[22]. - The cash and cash equivalents at the end of Q1 2025 were ¥402,713,740.07, up from ¥390,586,970.52 at the end of Q1 2024[22]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,987,730,433.46, a slight increase of 0.39% from ¥1,980,057,333.84 at the end of the previous year[4]. - Total liabilities were RMB 838,993,338.62 as of March 31, 2025, compared to RMB 835,659,103.08 at the end of 2024, indicating a marginal increase[13]. - The company reported a decrease in short-term borrowings to RMB 59,957,222.23 as of March 31, 2025, down 37.2% from RMB 95,584,422.23 at the end of 2024[12]. - Non-current assets totaled RMB 786,532,998.83 as of March 31, 2025, down 7.8% from RMB 853,055,497.57 at the end of 2024[12]. - Inventory increased to RMB 382,140,424.16 as of March 31, 2025, up 13.6% from RMB 336,323,956.50 at the end of 2024[11]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 26,463[7]. - The largest shareholder, Bailian Group Co., Ltd., holds 44.95% of the shares, totaling 100,274,734 shares[8]. - The company reported no significant changes in shareholder structure or participation in margin trading activities during the reporting period[9]. Other Financial Metrics - The weighted average return on equity decreased by 3.09 percentage points to 0.42% from 3.51% in the previous year[3]. - Non-recurring gains and losses totaled ¥243,605.32 for the period, with significant contributions from government subsidies and fair value changes of financial assets[5]. - Cash and cash equivalents as of March 31, 2025, were RMB 420,937,831.07, a decrease of 3.5% from RMB 436,420,035.77 as of December 31, 2024[11]. - The company reported a decrease in other comprehensive income, with a net amount of -¥464,615.21 for Q1 2025, compared to ¥961,573.32 in Q1 2024[17].